Ultragenyx settles DOJOLVI patent suit with Navinta; generic license starts January 1, 2033
Ultragenyx and Baylor Research Institute settled patent litigation with Navinta LLC over patents covering DOJOLVI oral liquid. Navinta will receive a non-exclusive, royalty-free license to market a generic version starting January 1, 2033, which would extend to July 1, 2033 if pediatric exclusivity is granted. The filing does not give a financial impact, and other ANDA patent litigation on DOJOLVI remains pending.
Key points
- Settlement with Navinta LLC resolves patent litigation filed in the U.S. District Court for the District of New Jersey
- Navinta's generic DOJOLVI license begins January 1, 2033, or July 1, 2033 if pediatric exclusivity is granted
- Similar patent litigation against other ANDA filers remains pending in the same court
- Settlement agreement will be submitted to the FTC and the U.S. Department of Justice
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 19, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.